CryoLife Receives CE Mark for On-X Ascending Aortic Prosthesis

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Who Is and Isn’t a Good Candidate for LASIK Surgery?

In the decades since its FDA approval, LASIK eye...

The Three Top Benefits of Opting for an Innovative Healthcare Practice

An innovative healthcare practice offers improved patient care through...

Remote Patient Monitoring: A Cost-Effective Solution for Patients and Health Facilities

Remote patient monitoring services are reshaping the healthcare landscape,...

PatientPoint improves health outcomes with new MyHealthTeam partnership

PatientPoint, one of the country’s leading digital health companies...

CryoLife Inc , a leading cardiac and vascular surgery company focused on aortic disease, announced it has received CE Mark for the On-X Ascending Aortic Prosthesis (AAP), allowing resumed distribution in the European Union. The On-X AAP is indicated for the treatment of diseased, damaged or malfunctioning native or prosthetic heart valves in the aortic position involving an ascending aortic aneurysm. These associated aortic root diseases coexist in as many as 10 percent of all aortic valve replacements.

“The absence of the On-X AAP from the market since late 2016 has hindered our ability to compete for certain mechanical valve tenders in the EU. With the receipt of the CE Mark on the AAP, we once again have a complete portfolio of On-X products available in Europe, allowing us to be more competitive and potentially drive market share gains in the mechanical valve market. The On-X AAP offers the best hemodynamics of any commercially available valved conduit device, and we will resume selling the On-X AAP in the EU immediately,” said Pat Mackin, Chairman, President, and Chief Executive Officer of CryoLife.

The On-X AAP is part of the On-X Heart Valve portfolio, which also includes the On-X® Aortic Valve and ON-X® Mitral Valve. The On-X Aortic Valve was the first mechanical aortic heart valve to receive both FDA and CE Mark approval for labeling to permit use with a reduced warfarin dosage, based on results of the original PROACT trial that demonstrated a greater than 60% reduction in bleeding events without increased risk of stroke. The On-X Mitral Valve is currently completing enrollment in its own PROACT (Lowered INR Mitral Arm) Prospective Randomized Clinical Trial, seeking a reduced warfarin indication similar to that of the On-X Aortic Valve.

About CryoLife, Inc.
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. CryoLife markets and sells products in more than 100 countries worldwide.

Latest stories

Related stories

Who Is and Isn’t a Good Candidate for LASIK Surgery?

In the decades since its FDA approval, LASIK eye...

The Three Top Benefits of Opting for an Innovative Healthcare Practice

An innovative healthcare practice offers improved patient care through...

Remote Patient Monitoring: A Cost-Effective Solution for Patients and Health Facilities

Remote patient monitoring services are reshaping the healthcare landscape,...

PatientPoint improves health outcomes with new MyHealthTeam partnership

PatientPoint, one of the country’s leading digital health companies...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back